Remove Access Remove DEA Remove Marijuana
article thumbnail

What Could Rescheduling Mean for Medical Cannabis Patients?

Canna Care Docs

Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”

Patients 111
article thumbnail

America’s Missed Opportunity in the Global Marijuana Market

Canna Law Blog

marijuana laws truly are. marijuana operators cant share in this enthusiasm. I use the word marijuana to refer to cannabis exceeding 0.3% Most countries with any type of marijuana program now acknowledge both medical and scientific marijuana. marijuana policy permits only marijuana for research purposes.

DEA 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Locked Out: SBA’s New Lending Policy Targets Hemp and Marijuana-Adjacent Businesses

Canna Law Blog

In yet another setback for hemp and marijuana-adjacent businesses, the U.S. In a previous post, Americas Missed Opportunity in the Global Marijuana Market , I outlined the broader systemic issues facing the marijuana industry. Cannabis is the plant species that includes both marijuana and hemp.

Policy 57
article thumbnail

The Hidden Potential Winners of Marijuana Rescheduling: DEA-Registered Bulk Manufacturers

Canna Law Blog

As the cannabis industry awaits potential marijuana rescheduling, eyes seem focused on state-legal operators and the tax relief they might enjoy. But there’s a group of players who’ve been surprisingly quiet, despite potentially having the most to gain: DEA-registered bulk marijuana manufacturers. billion by 2027.

DEA 69
article thumbnail

NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

NORML

The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.

article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 190
article thumbnail

House Passes Bipartisan Bill Facilitating Clinical Cannabis Research, Allowing Scientists to Access State-Approved Marijuana Products

NORML

The reality that most high-schoolers have easier access to cannabis than do our nation’s top scientists is the height of absurdity and an indictment of the current system.”. The post House Passes Bipartisan Bill Facilitating Clinical Cannabis Research, Allowing Scientists to Access State-Approved Marijuana Products appeared first on NORML.

Access 247